ITCI Intra-Cellular Therapies Inc

Price (delayed)

$35.43

Market cap

$2.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.23

Enterprise value

$2.83B

Sector: Healthcare
Industry: Biotechnology

Highlights

The revenue has soared by 119% from the previous quarter
The gross profit has soared by 116% from the previous quarter
ITCI's quick ratio has soared by 194% YoY but it is down by 5% from the previous quarter
The net income has plunged by 54% YoY and by 10% from the previous quarter
The debt has grown by 26% year-on-year

Key stats

What are the main financial stats of ITCI
Market
Shares outstanding
80.92M
Market cap
$2.87B
Enterprise value
$2.83B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.32
Price to sales (P/S)
109.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
124.25
Earnings
Revenue
$22.81M
EBIT
-$226.99M
EBITDA
-$226.46M
Free cash flow
-$230.34M
Per share
EPS
-$3.23
Free cash flow per share
-$3.27
Book value per share
$8.19
Revenue per share
$0.32
TBVPS
$10.19
Balance sheet
Total assets
$717.31M
Total liabilities
$60.45M
Debt
$29.14M
Equity
$656.86M
Working capital
$654.05M
Liquidity
Debt to equity
0.04
Current ratio
18.75
Quick ratio
18.17
Net debt/EBITDA
0.14
Margins
EBITDA margin
-992.7%
Gross margin
91.7%
Net margin
-995.1%
Operating margin
-1,013.6%
Efficiency
Return on assets
-37.7%
Return on equity
-41.7%
Return on invested capital
-53.6%
Return on capital employed
-33.4%
Return on sales
-995%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITCI stock price

How has the Intra-Cellular Therapies stock price performed over time
Intraday
-0.7%
1 week
-10.33%
1 month
4.18%
1 year
59.31%
YTD
11.42%
QTD
11.42%

Financial performance

How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$22.81M
Gross profit
$20.92M
Operating income
-$231.23M
Net income
-$227.01M
Gross margin
91.7%
Net margin
-995.1%
The revenue has soared by 119% from the previous quarter
The gross profit has soared by 116% from the previous quarter
The operating margin has soared by 100% YoY and by 50% from the previous quarter
The net margin has surged by 100% year-on-year and by 50% since the previous quarter

Growth

What is Intra-Cellular Therapies's growth rate over time

Valuation

What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
4.32
P/S
109.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
124.25
The EPS has contracted by 21% YoY
ITCI's P/B is 49% above its 5-year quarterly average of 2.9 and 31% above its last 4 quarters average of 3.3
The equity has declined by 7% since the previous quarter
The revenue has soared by 119% from the previous quarter
The stock's price to sales (P/S) is 99% less than its 5-year quarterly average of 20946.4 and 74% less than its last 4 quarters average of 425.7

Efficiency

How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 100% YoY and by 50% from the previous quarter
The ROE has grown by 32% YoY and by 14% from the previous quarter
ITCI's return on invested capital is up by 30% year-on-year and by 24% since the previous quarter
Intra-Cellular Therapies's ROA has increased by 24% YoY and by 12% from the previous quarter

Dividends

What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITCI.

Financial health

How did Intra-Cellular Therapies financials performed over time
The company's current ratio has surged by 195% YoY but it fell by 4.3% QoQ
ITCI's quick ratio has soared by 194% YoY but it is down by 5% from the previous quarter
The debt is 96% smaller than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.